Sartorius Stedim Biotech S.A.

For 2025, Sartorius reported sales revenue of slightly more than EUR 3.5 billion, up 7.6% in constant currencies and 4.7% reported. Underlying EBITDA was EUR 1.052 billion, up 11.2%, with margin at 29.7% (+170 bps). Underlying EPS grew 18%, operating cash flow was EUR 837 million, free cash flow was EUR 390 million, and CapEx was EUR 441 million, equal to a 12.5% ratio. Net debt to underlying EBITDA improved from 3.96x to 3.55x. For 2026, the group expects sales growth of around 5% to 9% in constant currencies and underlying EBITDA margin slightly above 30%; BPS is guided to 6% to 10% growth and margin slightly above 32%, while LPS is guided to 2% to 6% growth and margin slightly below 21%.

Michael Grosse framed 2025 as a year of normalization in consumables and cautious customer investment, but said Sartorius still delivered improved operational and financial performance. He emphasized that the company is entering 2026 with a strong order book, a more normal demand backdrop, and ongoing investment in innovation, manufacturing footprint, and customer proximity. His tone was confident but measured: management sees recovery continuing, yet explicitly warned that equipment and instruments have not fully returned to long-term growth levels.

Florian Funck highlighted that the business converted better demand into profit, with underlying EBITDA of EUR 1.052 billion and a 29.7% margin for the group. He pointed to positive volume and mix, scale effects, and cost discipline as the main drivers, while FX and tariffs were a headwind of around 1 percentage point; for 2026 he said tariffs alone imply about a 50 bps margin drag, with FX still uncertain. Cash generation was solid, with operating cash flow of EUR 837 million, free cash flow of EUR 390 million, and CapEx of EUR 441 million (12.5% of sales), while leverage improved to 3.55x and gross debt fell by EUR 277 million.

Analysts focused on whether 2026 guidance assumes equipment recovery, how much onshoring/reshoring could matter, and why LPS margins are guided lower despite better Q4 momentum. Management said no meaningful revenue from large-scale U.S. reshoring is assumed for 2026, and that equipment is expected to be at least stable rather than decline; upside would come from stronger consumables and some equipment recovery later in the year. On LPS, management said the lower margin guide reflects tariff and FX headwinds plus continued investment in Advanced Cell Models, while deferring deeper strategic discussion to the Capital Markets Day.